Analyst consensus rating
Protagonist Therapeutics Analyst Rating: Strong Buy
PTGX is rated Strong Buy by 13 analysts with a $170.38 target. As of 2026-08-27.
Direct answer
Protagonist Therapeutics's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $170.38.
Forecast evidence checked August 27, 2026.
Get free Protagonist Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $151.50
- Average price target
- $170.38
- High price target
- $225.00
- Low price target
- $149.00
- Low target gap
- -1.7%
- Target upside
- +12.5%
- High target gap
- +48.5%
- Target range width
- 50.2%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Protagonist Therapeutics?
Protagonist Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $170.38.
How far are Protagonist Therapeutics's low and high targets from the recorded price?
The low target implies -1.7%, while the high target implies +48.5%.
How many analysts are included in Protagonist Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is Protagonist Therapeutics's target upside or downside calculated?
The average target of $170.38 is divided by the recorded price of $151.50, then one is subtracted to produce +12.5%. This does not guarantee a future return.
When was Protagonist Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.